Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Sarcoma, Kaposi 4Neoplasms 4HIV Infections 4Acquired Immunodeficiency Syndrome 4

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × tecogalan × Sarcoma × Clear all
NCT00002136 2005-06-24

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002137 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002138 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002342 2005-06-24

A Study of Tecogalan Sodium

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡